Grey Wolf Therapeutics Raises $50 Million to Advance Clinical Trials and R&D
Grey Wolf Therapeutics Closes $50M Series B Financing Expansion
Grey Wolf Therapeutics' Series B Extension Funding
Key Highlights:
- Series B Extension Funding: Raised $50 million in Series B extension funding, bringing the total amount raised to $99 million.
- Investors: Led by ICG's Life Sciences team, with participation from existing investors Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises, and British Patient Capital.
- Research and Development: Funds will be used to broaden the ongoing Phase 1/2 clinical trial of GRWD5769, Grey Wolf's lead immuno-oncology candidate, and expand R&D for antigen modulation treatments in autoimmune diseases.
Grey Wolf Therapeutics' Target Market
- Target Market: Focus on developing antigen modulation therapies for solid tumor types and autoimmune diseases.
- Oncology Treatment Providers: Collaboration opportunities with oncology clinics and hospitals for clinical trials and potential future partnerships.
- Autoimmune Disease Specialists: Engaging with healthcare professionals specializing in autoimmune diseases for research and development collaborations.
What Grey Wolf Therapeutics Needs to Buy
- Clinical Research Services: Partnerships with research organizations and clinical trial providers for conducting trials and gathering data.
- Manufacturing and Supply Chain Solutions: Collaborating with manufacturers for the production of their therapeutic candidates and managing a reliable supply chain.
- Regulatory and Compliance Expertise: Engaging with regulatory consultants and experts to navigate the complex landscape of drug development and compliance.